Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, pertuzumab, and trastuzumab for reimbursement as a treatment option for the neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence.
This is written in the approval document as:
Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.
Citation
DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Pertuzumab, Trastuzumab |